ISB News

Baliga Lab: Uncovering the Genetic Adaptability of Tuberculosis

3 Bullets:

  • The Institute for Systems Biology and Seattle BioMed have collaborated to reconstruct the gene regulatory network of the human pathogen Mycobacterium tuberculosis.
  • Finely tuned gene regulation has allowed Mycobacterium tuberculosis to survive unnoticed in an apparently healthy host for decades; understanding those subtleties is critical for advancing treatment.
  • The identification of co-regulated sets of genes and their regulatory influences offers validated predictions that will help guide future research into Mycobacterium tuberculosis pathogenicity.

By Jake Valenzuela and Eliza Peterson

Tuberculosis, responsible for nearly two million deaths each year, is caused by the bacterium Mycobacterium tuberculosis (MTB). Researchers from the Institute of Systems Biology in collaboration with Seattle BioMed have undertaken a comprehensive approach centered around the strengths of systems biology to identify adaptive regulatory mechanisms employed by MTB.

Journal: Nucleic Acids Research
Title: A high-resolution network model for global gene regulation in Mycobacterium tuberculosis
Authors: Eliza J.R. Peterson, David J. Reiss, Serdar Turkarslan, Kyle J. Minch, Tige Rustad, Christopher L. Plaisier, William J.R. Longabaugh, David R. Sherman, Nitin S. Baliga
Link: http://nar.oxfordjournals.org/content/early/2014/09/17/nar.gku777.full

The success of MTB as a human pathogen is largely due to its ability to alter gene expression and adapt to the complex host environment within which it resides. In an effort to model the gene regulation of this elusive microorganism, researchers compiled 2,325 publicly available gene expression profiles from a diverse set of conditions and constructed a gene regulatory network model of MTB. The gene regulatory network model predicts sets of genes that are similarly expressed, the proteins or factors that bind to DNA to influence their gene expression, and the environmental conditions in which these regulatory interactions occur. This global analysis gives us a clearer idea of MTB pathogenicity and, by engaging in a systems biology approach, we better understand how the pathogen responds to a diversity of stress conditions like low oxygen, host interactions, and nutrient availability. In particular, the researchers highlighted the importance of host cholesterol availability during infection and provided new details about the regulation of cholesterol utilization in MTB.

Importantly, the gene regulatory network of MTB was made publicly available (http://networks.isbscience.net/mtb/) to encourage exploration of the model. This will hopefully drive future efforts toward understanding how MTB responds to various environmental conditions, including those responsible for pathogenicity. This network also laid the foundation for future versions of the model that will incorporate new data and new modeling techniques.

Read more about ISB’s work with Tuberculosis: ISB Researchers Identify New Protein Modification Critical Growth of Tuberculosis Pathogen

About Dr. Jake Valenzuela and Dr. Eliza Peterson: Jake is a postdoc in the Baliga Lab and a member of the ISB Editorial Board. Eliza is postdoc in the Baliga Lab and lead author of the paper.

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.